Terms: = Bone cancer AND IDH1, IDP, 3417, ENSG00000138413, IDH, PICD, O75874 AND Prognosis
54 results:
1. Innovations in conditioning and post-transplant maintenance in AML: genomically informed revelations on the graft-versus-leukemia effect.
Murdock HM; Ho VT; Garcia JS
Front Immunol; 2024; 15():1359113. PubMed ID: 38571944
[TBL] [Abstract] [Full Text] [Related]
2. SMARCB1-Deficient Skull Base Chondrosarcoma with 12p Duplication Presenting as Somatic-Type Malignancy Arising from Metastatic Seminoma.
Argyris PP; Challa B; Satturwar S; VanKoevering KK; Wakely PE
Head Neck Pathol; 2024 Jan; 18(1):1. PubMed ID: 38236556
[TBL] [Abstract] [Full Text] [Related]
3. Diagnosis- and prognosis-Related Gene Alterations in
Morishita S; Komatsu N
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629188
[No Abstract] [Full Text] [Related]
4. Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.
Tefferi A; Alkhateeb H; Gangat N
Blood Cancer J; 2023 Jul; 13(1):108. PubMed ID: 37460550
[TBL] [Abstract] [Full Text] [Related]
5. Distinct idh1/2-associated Methylation Profile and Enrichment of
Dermawan JKT; Nafa K; Mohanty A; Xu Y; Rijo I; Casanova J; Villafania L; Benhamida J; Kelly CM; Tap WD; Boland PJ; Fabbri N; Healey JH; Ladanyi M; Lu C; Hameed M
Cancer Res Commun; 2023 Mar; 3(3):431-443. PubMed ID: 36926116
[TBL] [Abstract] [Full Text] [Related]
6. Clinical utility of genomic profiling of AML using paraffin-embedded bone marrow clots: HM-SCREEN-Japan 01.
Hosono N; Chi S; Yamauchi T; Fukushima K; Shibayama H; Katagiri S; Gotoh A; Eguchi M; Morishita T; Ogasawara R; Kondo T; Yanada M; Yamamoto K; Kobayashi T; Kuroda J; Usuki K; Utsu Y; Yoshimitsu M; Ishitsuka K; Ono T; Takahashi N; Iyama S; Kojima K; Nakamura Y; Fukuhara S; Izutsu K; Abutani H; Yamauchi N; Yuda J; Minami Y;
Cancer Sci; 2023 May; 114(5):2098-2108. PubMed ID: 36793248
[TBL] [Abstract] [Full Text] [Related]
7. Biology and Management of High-Grade Chondrosarcoma: An Update on Targets and Treatment Options.
Tlemsani C; Larousserie F; De Percin S; Audard V; Hadjadj D; Chen J; Biau D; Anract P; Terris B; Goldwasser F; Pasmant E; Boudou-Rouquette P
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674874
[TBL] [Abstract] [Full Text] [Related]
8. Molecular genetic characterization of Philadelphia chromosome-positive acute myeloid leukemia.
Zhou Q; Zhao D; Eladl E; Capo-Chichi JM; Kim DDH; Chang H
Leuk Res; 2023 Jan; 124():107002. PubMed ID: 36563650
[TBL] [Abstract] [Full Text] [Related]
9. A specific immune signature for predicting the prognosis of glioma patients with idh1-mutation and guiding immune checkpoint blockade therapy.
Zeng Z; Hu C; Ruan W; Zhang J; Lei S; Yang Y; Peng P; Pan F; Chen T
Front Immunol; 2022; 13():1001381. PubMed ID: 36159801
[TBL] [Abstract] [Full Text] [Related]
10. Natural Coevolution of Tumor and Immunoenvironment in Glioblastoma.
Wu L; Wu W; Zhang J; Zhao Z; Li L; Zhu M; Wu M; Wu F; Zhou F; Du Y; Chai RC; Zhang W; Qiu X; Liu Q; Wang Z; Li J; Li K; Chen A; Jiang Y; Xiao X; Zou H; Srivastava R; Zhang T; Cai Y; Liang Y; Huang B; Zhang R; Lin F; Hu L; Wang X; Qian X; Lv S; Hu B; Zheng S; Hu Z; Shen H; You Y; Verhaak RGW; Jiang T; Wang Q
Cancer Discov; 2022 Dec; 12(12):2820-2837. PubMed ID: 36122307
[TBL] [Abstract] [Full Text] [Related]
11. A genetic model for central chondrosarcoma evolution correlates with patient outcome.
Cross W; Lyskjær I; Lesluyes T; Hargreaves S; Strobl AC; Davies C; Waise S; Hames-Fathi S; Oukrif D; Ye H; Amary F; Tirabosco R; Gerrand C; Baker T; Barnes D; Steele C; Alexandrov L; Bond G; ; Cool P; Pillay N; Van Loo P; Flanagan AM
Genome Med; 2022 Aug; 14(1):99. PubMed ID: 36042521
[TBL] [Abstract] [Full Text] [Related]
12. Periosteal chondrosarcoma: A case series in a referral center with survivorship analysis.
Pacheco M; Barra L; Gambarotti M; Magagnoli G; Sbaraglia M; Asioli S; Cocchi S; Carretta E; Frisoni T; Benini S; Dei Tos AP; Righi A
Eur J Surg Oncol; 2022 Aug; 48(8):1730-1738. PubMed ID: 35690562
[TBL] [Abstract] [Full Text] [Related]
13. [Clinical Significance of Low Expression of LncRNA CASC15 in Acute Myeloid Leukemia with NPM1 Mutations].
Xia PH; Xu ZJ; Jin Y; Ma JC; Wen XM; Yuan Q; Leng JY; Qian J; Lin J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):659-670. PubMed ID: 35680788
[TBL] [Abstract] [Full Text] [Related]
14. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.
Pasca S; Chifotides HT; Verstovsek S; Bose P
Int Rev Cell Mol Biol; 2022; 366():83-124. PubMed ID: 35153007
[TBL] [Abstract] [Full Text] [Related]
15. Pharmacological inhibition of Carbonic Anhydrase IX and XII to enhance targeting of acute myeloid leukaemia cells under hypoxic conditions.
Chen F; Licarete E; Wu X; Petrusca D; Maguire C; Jacobsen M; Colter A; Sandusky GE; Czader M; Capitano ML; Ropa JP; Boswell HS; Carta F; Supuran CT; Parkin B; Fishel ML; Konig H
J Cell Mol Med; 2021 Dec; 25(24):11039-11052. PubMed ID: 34791807
[TBL] [Abstract] [Full Text] [Related]
16. Driver Genetic Mutations in Spinal Cord Gliomas Direct the Degree of Functional Impairment in Tumor-Associated Spinal Cord Injury.
Nagashima Y; Nishimura Y; Ohka F; Eguchi K; Aoki K; Ito H; Nishii T; Oyama T; Hara M; Kitano Y; Masaki H; Wakabayashi T; Natsume A
Cells; 2021 Sep; 10(10):. PubMed ID: 34685506
[TBL] [Abstract] [Full Text] [Related]
17. Prognostic impact of idh mutations in chondrosarcoma.
Nakagawa M; Sekimizu M; Endo M; Kobayashi E; Iwata S; Fukushima S; Yoshida A; Kitabayashi I; Ichikawa H; Kawai A; Nakatani F
J Orthop Sci; 2022 Nov; 27(6):1315-1322. PubMed ID: 34531086
[TBL] [Abstract] [Full Text] [Related]
18. Circulating tumour DNA is a promising biomarker for risk stratification of central chondrosarcoma with idh1/2 and GNAS mutations.
Lyskjaer I; Davies C; Strobl AC; Hindley J; James S; Lalam RK; Cross W; Hide G; Rankin KS; Jeys L; Tirabosco R; Stevenson J; ; O'Donnell P; Cool P; Flanagan AM
Mol Oncol; 2021 Dec; 15(12):3679-3690. PubMed ID: 34528398
[TBL] [Abstract] [Full Text] [Related]
19. [Clinical impact of gene mutations on myeloproliferative neoplasms in Japan].
Morishita S
Rinsho Ketsueki; 2021; 62(8):1060-1069. PubMed ID: 34497192
[TBL] [Abstract] [Full Text] [Related]
20. Single-cell characterization of macrophages in glioblastoma reveals MARCO as a mesenchymal pro-tumor marker.
Chen AX; Gartrell RD; Zhao J; Upadhyayula PS; Zhao W; Yuan J; Minns HE; Dovas A; Bruce JN; Lasorella A; Iavarone A; Canoll P; Sims PA; Rabadan R
Genome Med; 2021 May; 13(1):88. PubMed ID: 34011400
[TBL] [Abstract] [Full Text] [Related]
[Next]
